HUE059945T2 - Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok - Google Patents
Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorokInfo
- Publication number
- HUE059945T2 HUE059945T2 HUE18836520A HUE18836520A HUE059945T2 HU E059945 T2 HUE059945 T2 HU E059945T2 HU E18836520 A HUE18836520 A HU E18836520A HU E18836520 A HUE18836520 A HU E18836520A HU E059945 T2 HUE059945 T2 HU E059945T2
- Authority
- HU
- Hungary
- Prior art keywords
- heterocyclic compounds
- bicyclic heterocyclic
- substituted bicyclic
- prmt5 inhibitors
- prmt5
- Prior art date
Links
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101150097768 prmt5 gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201721044886 | 2017-12-13 | ||
IN201821024634 | 2018-07-02 | ||
IN201821040029 | 2018-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE059945T2 true HUE059945T2 (hu) | 2023-01-28 |
Family
ID=65036860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE18836520A HUE059945T2 (hu) | 2017-12-13 | 2018-12-13 | Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok |
Country Status (28)
Country | Link |
---|---|
US (2) | US11459330B2 (hu) |
EP (1) | EP3724190B1 (hu) |
JP (1) | JP7282778B2 (hu) |
KR (1) | KR20200098598A (hu) |
CN (1) | CN111712498B (hu) |
AU (1) | AU2018385664B2 (hu) |
BR (1) | BR112020011746A2 (hu) |
CA (1) | CA3085259A1 (hu) |
CL (1) | CL2020001576A1 (hu) |
CR (1) | CR20200263A (hu) |
CU (1) | CU24621B1 (hu) |
DK (1) | DK3724190T3 (hu) |
ES (1) | ES2927860T3 (hu) |
GE (1) | GEP20227359B (hu) |
HR (1) | HRP20221207T1 (hu) |
HU (1) | HUE059945T2 (hu) |
IL (1) | IL274936B2 (hu) |
LT (1) | LT3724190T (hu) |
MX (1) | MX2020006181A (hu) |
PE (1) | PE20211444A1 (hu) |
PH (1) | PH12020550881A1 (hu) |
PL (1) | PL3724190T3 (hu) |
PT (1) | PT3724190T (hu) |
RS (1) | RS63623B1 (hu) |
SG (1) | SG11202004934QA (hu) |
UA (1) | UA126349C2 (hu) |
WO (1) | WO2019116302A1 (hu) |
ZA (1) | ZA202003528B (hu) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
KR20210089656A (ko) | 2018-10-05 | 2021-07-16 | 버텍스 파마슈티칼스 인코포레이티드 | 알파-1 항트립신 조절제 |
JP2022522534A (ja) * | 2019-04-02 | 2022-04-19 | アリゴス セラピューティクス インコーポレイテッド | Prmt5を標的にする化合物 |
US11884672B2 (en) | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
AU2020283505A1 (en) * | 2019-05-30 | 2021-12-23 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as PRMT5 inhibitors |
RS64972B1 (sr) * | 2019-06-10 | 2024-01-31 | Lupin Ltd | Inhibitori prmt5 |
EP4048270A1 (en) * | 2019-10-22 | 2022-08-31 | Lupin Limited | Pharmaceutical combination of prmt5 inhibitors |
CN115279756A (zh) * | 2019-10-25 | 2022-11-01 | 埃克森特治疗公司 | Mettl3调节剂 |
JP2023504279A (ja) | 2019-12-03 | 2023-02-02 | ルピン・リミテッド | Prmt5阻害剤としての置換ヌクレオシドアナログ |
WO2021202480A1 (en) * | 2020-04-01 | 2021-10-07 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
EP4126819A1 (en) * | 2020-04-03 | 2023-02-08 | Vertex Pharmaceuticals Incorporated | 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd) |
CA3176912A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers |
JP2024502886A (ja) | 2021-01-19 | 2024-01-23 | ルピン・リミテッド | がんを処置及び/又は予防するためのsos1阻害薬の医薬組合せ |
CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003251431A1 (en) | 2002-07-22 | 2004-02-09 | Cambridge University Technical Services Ltd. | Synthesis of discodermolide |
WO2005016878A2 (en) | 2003-08-13 | 2005-02-24 | Isis Pharmaceuticals, Inc. | METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
JP2009539815A (ja) | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のa5b1アンタゴニストとしてのN−(ベンゾイル)−O−[2−(ピリジン−2−イルアミノ)エチル]−L−チロシン誘導体と関連化合物 |
AU2008223793B2 (en) | 2007-03-08 | 2012-08-23 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
FR2926556B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
US20110237606A1 (en) | 2008-09-26 | 2011-09-29 | Agency Of Science, Technology And Research | 3-Deazaneplanocin Derivatives |
WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
ES2689103T3 (es) | 2010-06-30 | 2018-11-08 | Fujifilm Corporation | Nuevo derivado de nicotinamida o sal del mismo |
WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
JP5964426B2 (ja) | 2011-08-19 | 2016-08-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッドGlaxosmithkline Intellectual Property No.2 Limited | 脂肪酸シンターゼ阻害剤 |
IN2012CH01573A (hu) * | 2012-04-20 | 2015-07-10 | Advinus Therapeutics Ltd | |
PT2861604T (pt) | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
WO2014008223A2 (en) | 2012-07-03 | 2014-01-09 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
PT2935222T (pt) | 2012-12-21 | 2018-12-10 | Epizyme Inc | Inibidores de prmt5 e seus usos |
CA2894157A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US8940726B2 (en) | 2012-12-21 | 2015-01-27 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
EP2935241A1 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
EP2935240A1 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
CA2942833A1 (en) | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
CN106488910B (zh) | 2013-10-10 | 2020-07-31 | 亚瑞克西斯制药公司 | Kras g12c的抑制剂 |
CA2943882A1 (en) | 2014-05-22 | 2015-11-26 | F. Hoffmann-La Roche Ag | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives |
US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
EP3160466A4 (en) | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
MX2017000134A (es) | 2014-06-25 | 2017-05-01 | Glaxosmithkline Ip Dev Ltd | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3 ,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carb oxamida. |
CA2953572A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2016034671A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors |
EP3189041B1 (en) | 2014-09-03 | 2021-04-28 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
WO2016038550A1 (en) | 2014-09-11 | 2016-03-17 | Novartis Ag | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
CU20170105A7 (es) | 2015-02-24 | 2017-10-05 | Pfizer | Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos |
EP3268044A2 (en) | 2015-03-11 | 2018-01-17 | The Broad Institute Inc. | Prmt5 inhibitors for the treatment of cancer with reduced mtap activty |
AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
TW202321249A (zh) | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
CN108779097A (zh) | 2015-11-16 | 2018-11-09 | 亚瑞克西斯制药公司 | 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法 |
EA201990851A1 (ru) * | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
-
2018
- 2018-12-13 AU AU2018385664A patent/AU2018385664B2/en active Active
- 2018-12-13 EP EP18836520.9A patent/EP3724190B1/en active Active
- 2018-12-13 PL PL18836520.9T patent/PL3724190T3/pl unknown
- 2018-12-13 HR HRP20221207TT patent/HRP20221207T1/hr unknown
- 2018-12-13 PE PE2020000761A patent/PE20211444A1/es unknown
- 2018-12-13 HU HUE18836520A patent/HUE059945T2/hu unknown
- 2018-12-13 CU CU2020000051A patent/CU24621B1/es unknown
- 2018-12-13 CN CN201880089329.6A patent/CN111712498B/zh active Active
- 2018-12-13 IL IL274936A patent/IL274936B2/en unknown
- 2018-12-13 KR KR1020207019844A patent/KR20200098598A/ko not_active Application Discontinuation
- 2018-12-13 CA CA3085259A patent/CA3085259A1/en active Pending
- 2018-12-13 JP JP2020532614A patent/JP7282778B2/ja active Active
- 2018-12-13 BR BR112020011746-3A patent/BR112020011746A2/pt unknown
- 2018-12-13 MX MX2020006181A patent/MX2020006181A/es unknown
- 2018-12-13 WO PCT/IB2018/060015 patent/WO2019116302A1/en unknown
- 2018-12-13 CR CR20200263A patent/CR20200263A/es unknown
- 2018-12-13 DK DK18836520.9T patent/DK3724190T3/da active
- 2018-12-13 UA UAA202004140A patent/UA126349C2/uk unknown
- 2018-12-13 ES ES18836520T patent/ES2927860T3/es active Active
- 2018-12-13 PT PT188365209T patent/PT3724190T/pt unknown
- 2018-12-13 SG SG11202004934QA patent/SG11202004934QA/en unknown
- 2018-12-13 LT LTEPPCT/IB2018/060015T patent/LT3724190T/lt unknown
- 2018-12-13 RS RS20220931A patent/RS63623B1/sr unknown
- 2018-12-13 GE GEAP201815385A patent/GEP20227359B/en unknown
- 2018-12-13 US US16/772,959 patent/US11459330B2/en active Active
-
2020
- 2020-06-06 PH PH12020550881A patent/PH12020550881A1/en unknown
- 2020-06-11 CL CL2020001576A patent/CL2020001576A1/es unknown
- 2020-06-12 ZA ZA2020/03528A patent/ZA202003528B/en unknown
-
2022
- 2022-05-06 US US17/738,370 patent/US11952380B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202003528B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
ZA202003778B (en) | Heterocyclic compounds as prmt5 inhibitors | |
IL289793A (en) | Heterocyclic compounds as ret kinase inhibitors | |
IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
IL267781A (en) | Heterocyclic spiro compounds as magl inhibitors | |
IL269188A (en) | The heterocyclic compounds useful as dual inhibitors of ATX / CA. | |
IL273428B1 (en) | Heterocyclic compounds as pad inhibitors | |
PL3371190T3 (pl) | Związki heterocykliczne jako inhibitory pi3k-gamma | |
HRP20221051T1 (hr) | Heterociklički spojevi kao inhibitori ret kinaze | |
IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
SG11202005112TA (en) | Heterocyclic compounds as prmt5 inhibitors | |
SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
IL262448B (en) | Disubstituted heterocyclic bicyclic compounds |